{"id":"W4402559864","doi":"10.1016/j.annonc.2024.08.812","title":"751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Tolerability; Bevacizumab; Carboplatin; Paclitaxel; Oncology; Internal medicine; Ovarian cancer; Chemotherapy; Cancer; Adverse effect; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004573802,0.0003904419,0.0008483652,0.0001336571,0.0001502669,0.0006637432,0.0002999084,0.0004104807,0.002929852],"category_scores_gemma":[0.0007643838,0.000193751,0.0005652258,0.0001994924,0.0002568636,0.0004274631,0.0001424058,0.001306131,0.000461352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006583554,"about_ca_system_score_gemma":0.0005182795,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001386214,"about_ca_topic_score_gemma":0.003250292,"domain_scores_codex":[0.9998141,0.00007032859,0.000008564703,0.00003651673,0.00001926349,0.00005119823],"domain_scores_gemma":[0.9997571,0.00006020116,0.00004642363,0.00001564284,0.00001033808,0.0001101883],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7480832,0.005625697,0.01644665,0.0004917326,0.001816135,0.0003003749,0.0001591453,0.003179808,0.03021941,0.0004296457,0.005124254,0.188124],"study_design_scores_gemma":[0.4416651,0.3841621,0.1406232,0.0001505867,0.00275529,0.001314389,0.0002034096,0.005270364,0.0105379,0.0009181396,0.0123075,0.00009182531],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948502,0.001961468,0.0001214448,0.0002551661,0.00005392419,0.0000891254,0.0006804936,0.00002914398,0.001958947],"genre_scores_gemma":[0.9974555,0.0006233811,0.0001212676,0.0002116831,0.00003850568,0.00005602853,0.0006227188,0.000008672701,0.0008621594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002929852,"threshold_uncertainty_score":0.009801388,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02996050006913973,"score_gpt":0.3745074189386176,"score_spread":0.3445469188694778,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}